The Patent Finder

Artecel, Inc.

Also on record
Records under this name other than patents Artecel, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Artecel, Inc.

PatentTitleStatus Expires Confidence
US 9,249,393Adipose Derived Adult Stem Cells in Hepatic Regeneration
Formerly held
Lapsed on the fee record
Ended Feb 2, 2024 · High confidence
Lapsed on the fee recordEnded Feb 2, 2024High confidence
US 6,555,374Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
Formerly held
Term ended
Term ended Dec 10, 2020 · From the USPTO record
Term endedTerm ended Dec 10, 2020From the USPTO record
US 6,242,200Screening for SUR1 antagonists using adipocytes
Formerly held
Term ended
Term ended Jun 12, 2020 · From the USPTO record
Term endedTerm ended Jun 12, 2020From the USPTO record
US 6,391,297Differentiation of adipose stromal cells into osteoblasts and uses thereof
Formerly held
Term ended
Term ended May 19, 2020 · From the USPTO record
Term endedTerm ended May 19, 2020From the USPTO record
US 6,429,013Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Formerly held
Term ended
Term ended May 17, 2020 · From the USPTO record
Term endedTerm ended May 17, 2020From the USPTO record
US 9,255,249Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
Formerly held
Lapsed on the fee record
Ended Feb 9, 2020 · From the USPTO record
Lapsed on the fee recordEnded Feb 9, 2020From the USPTO record
US 9,200,255Differentiation of adipose stromal cells into osteoblasts and treating bones
Formerly held
Lapsed on the fee record
Ended Dec 1, 2019 · From the USPTO record
Lapsed on the fee recordEnded Dec 1, 2019From the USPTO record
US 8,048,673Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Formerly held
Lapsed on the fee record
Ended Nov 1, 2019 · From the USPTO record
Lapsed on the fee recordEnded Nov 1, 2019From the USPTO record
US 6,100,047Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Formerly held
Term ended
Term ended Apr 7, 2019 · From the USPTO record
Term endedTerm ended Apr 7, 2019From the USPTO record
US 6,492,130Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Formerly held
Term ended
Ended no later than Apr 7, 2019 · From the USPTO record
Term endedEnded no later than Apr 7, 2019From the USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited